Alzheimer disease (AD) is the most common form of dementia. AD is characterized by amyloid plaques and neurofibrillary tangles in the brain, with associated loss of synapses and neurons, … [Read more...] about TAU Me One More Time
Novo Nordisk (NYSE: NVO) is a global healthcare company engaged in diabetes care, obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other … [Read more...] about Is Novo Nordisk Ready For Increased Biosimilar Competition?
Introduction Trevena Inc. (Nasdaq: TRVN) spiked 119% from the $.5 range to $1.19 on January 28th. The catalyst being positive regulatory updates from the FDA Type A meeting minutes. In a nut-shell the … [Read more...] about 2019 Should Be A Good Year For TRVN, But What’s Next?
Leave a comment and click here to sub for MS Equity Analysis and Swing Moves. Introduction You may have recently seen hype about Corbus Pharmaceuticals (Nasdaq: CRBP), … [Read more...] about CRBP – Is Corbus Pharmaceuticals a good buy?
Introduction Bristol-Myers Squibb (NYSE: BMY) is a profitable global bio-pharmaceutical company targeting an array of serious diseases and unmet medical needs. Earlier this month BMY announced … [Read more...] about Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market
Leave a comment and click here to sub for MS article alerts and our newsletter! What's new? VSTM added to NASDAQ Biotech Index Hedge funds increase positions Analysts maintain $10+ PT … [Read more...] about Where Is VSTM Headed?